AstraZeneca
AstraZeneca snubs Pfizer’s “opportunistic” bid
13 May 2014
Pfizer seeks to allay fears over AstraZeneca deal
07 May 2014
Pfizer says the merger with AstraZeneca would bolster innovative science and speed up the development of new treatments
Cable admits Pfizer-AstaraZeneca deal involves ‘national interest’ issues
05 May 2014
Britain’s Business Secretary Vince Cable said late on Sunday that the bid by Pfizer Inc for AstraZeneca Plc raised questions of “overriding national interest”, as the opposition Labour Party stepped up its campaign against the proposed takeover
AstraZeneca rejects Pfizer’s revised $106 billion offer
02 May 2014
Today’s 50 pounds ($84.47) a share indicative offer followed AstraZeneca's decision to reject an earlier proposal that valued it at 46.61 pounds per share
AstraZeneca to consider Pfizer’s $106-bn bid
02 May 2014
The announcement comes just days after AstraZeneca Plc denied plans to discuss any partnership proposals with Pfizer
Pfizer confirms AstraZeneca's rejection; to explore options
28 Apr 2014
US drugs giant Pfizer today confirmed that it had made a $98.67 billion (£58.73 billion) takeover offer for AstraZeneca, which was rejected by the UK-based company
Pfizer weighs $101-bn bid for AstraZeneca
21 Apr 2014
A potential deal with AstraZeneca would be the biggest-ever acquisition in the pharmaceutical industry, and would see another iconic British brand being acquired by a foreign company
AstraZeneca to acquire Bristol-Myers Squibb’s stake in diabetes business
20 Dec 2013
The acquisition will boost AstraZeneca's presence in the emerging markets, where diabetes is a fast-growing problem and by 2030, is expected to accout of two-thirds of the world's diabetic population
S Korean companies Hanmi and Amneal Pharm launch first copy of AstraZeneca's Nexium in US
20 Dec 2013
AstraZeneca site to emerge as biotech hub
08 May 2013
The BioHub at AstraZeneca's site provides 36,000 sq ft of high-end laboratory and office facilities for early-stage and growing firms engaged in innovative drug discovery and development
AstraZeneca to eliminate 1,600 jobs in major R&D restructuring
19 Mar 2013
Pascal Soriot, CEO says the overhaul would lead to $1.4 billion in one-time restructuring charges, with annualised benefits expected to reach approximately $190 million by 2016
Featured articles
Lighter than air, yet very, very powerful
By Kiron Kasbekar | 03 Jan 2024
In March 2013 Chinese scientists pulled off a remarkable feat. They created the world’s lightest aerogel. Tipping the scales at a mere 0.16 milligrams per cubic centimeter – that’s a sixth of the weight of air!
COP28 explained: A closer look at COP28's climate change solutions
By Aniket Gupta | 27 Dec 2023
The 28th United Nations Climate Change Conference, also known as COP28, took place from 30th November 2023, to 13th December 2023, at Expo City in Dubai, United Arab Emirates.
What is a Ponzi scheme?
By Aniket Gupta | 06 Dec 2023
Ponzi schemes have long captivated the public imagination, drawing unsuspecting investors into a web of illusion and deception.
The Rise and Rise of HDFC Bank
03 Jul 2023
HDFC, which surged ahead of global majors like HSBC Holdings Plc and Citigroup Inc and left Indian peers like State Bank of India and ICICI Bank in market capitalisation, now ranks fourth largest among the world’s most valuable banks, after JPMorgan Chase & Co, Industrial and Commercial Bank of China Ltd and Bank of America Corp
India’s Millet Revolution To Enrich Global Food Basket
02 Apr 2023
Millets, a healthier and cheaper substitute to wheat and rice, are indigenous to many parts of the world, especially in the semiarid tropics of Asia and Africa, and offers a big scope for expanding production and consumption in the foodgrain deficient African continent
Market predator Hindenburg preys on Adani stock
06 Mar 2023
Almost a month after the damning report of short-seller Hindenburg Research on the Adani Group that claimed that the seven stocks within the group were about 85 per cent overvalued, one of the group's stocks, Adani Total Gas, closed at Rs835 on the BSE, down nearly 79 per cent from its 24 January level, almost close to reaching that valuation
.jpg "Microsoft, Google challenge Delhi HC order to remove non-consensual content")
